Qiming Venture Partners Weekly | Top 10 Portfolio Company Updates Vol.30, Sept. 16, 2026
Celebrating milestone moments with Qiming Venture Partners portfolio companies
Editor's Note: In 2026, the Qiming Weekly has been upgraded and refreshed, with regular updates every week featuring only ten major developments from Qiming Venture Partners portfolio companies, covering funding progress and breakthroughs. In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and join you in marking the milestone moments of our portfolio companies.
Funding
Xuntu Technology Closes Over RMB 300 Million Series B Round
Recently, Qiming Venture Partners portfolio company and financial AI firm Xuntu Technology closed an oversubscribed Series B round of over RMB 300 million, its third funding round completed within the past year. This round attracted insurance capital, securities firms, strategic investors, and leading venture capital institutions, with existing shareholders including Qiming Venture Partners continuing their support. Following this round, Xuntu Technology will further increase investment in model and product technology, expand its diverse asset customer base, deepen upstream and downstream industry collaboration, and steadily advance its overseas footprint while maintaining its focus on the domestic market.
**Xuntu Technology's AI research assistant Alpha Pi has served over 120,000 professional users, covering more than 8,000 financial and asset management institutions. In April 2026, the company launched the industry's first AI research workstation, PaiWork, integrating financial data, research tools, and knowledge bases into a unified workspace; in June, it introduced the iRaB research practice evaluation system and initiated the ORE ecosystem partnership program, collaborating with over 40 securities research institutes and data service providers.
Major Partnerships
01/
WeRide Secures Spain's First L4 Autonomous Passenger Vehicle Operating License
Recently, Qiming Venture Partners portfolio company and global leading autonomous driving technology firm WeRide (NASDAQ: WRD, 00800.HK) jointly announced with international mobility service giant Uber and Moove Cars Group's autonomous driving business unit AVOMO that, with the support of the Madrid government, the three parties have officially obtained Spain's first L4 autonomous passenger vehicle operating license issued by the Spanish Directorate-General for Traffic (DGT) under the ES-AV framework, permitting deployment on public roads.
This marks the first time Spain has opened national-level access for L4 Robotaxi at the national level, setting a new regulatory benchmark for autonomous driving commercialization in Europe. Upon completion of preparatory work and fulfillment of operational and regulatory requirements, the three parties expect to launch commercial Robotaxi services for the public in 2026, allowing Madrid users to hail a WeRide Robotaxi with one tap on the Uber App. Madrid is the fourth city in WeRide and Uber's strategic cooperation roadmap, with plans to expand their Robotaxi partnership to 15 cities globally by 2030.
02/
Cornerstone Robotics Enters Strategic Partnership with Beijing Shijitan Hospital, Capital Medical University
Recently, Qiming Venture Partners portfolio company Cornerstone Robotics's Sentire® laparoscopic surgical robot surpassed 200 clinical applications at Beijing Shijitan Hospital, Capital Medical University, and the two parties formally established a strategic partnership.
At the live surgery session of the 2026 World Urology Academic Conference and the 2nd Capital Medical University Urology Academic Frontier Exchange Conference, Professor Xing Nianzeng successfully performed a challenging retzius-sparing robot-assisted laparoscopic radical prostatectomy using the Sentire® system. Building on the mutual trust established through 200 clinical cases, the two parties will center on collaborative medical-industrial innovation and integrated industry-academia-research-application, constructing a full-chain ecosystem covering clinical diagnosis and treatment, technology R&D, talent cultivation, and成果转化. Guowei Ou, founder and CEO of Cornerstone Robotics, was also appointed as visiting professor at the Capital Medical University Cancer Hospital.
Product Launches
01/
Shengshu Technology Releases Self-Evolving General World Model Motus2
Recently, at the 2026 Bund Summit, Yihang Luo, co-founder and CEO of Qiming Venture Partners portfolio company Shengshu Technology, delivered a keynote speech titled "Seeing the Future Before Acting: From First Principles of World Models", systematically presenting Shengshu Technology's understanding of the General World Model (GWM) and its five-level development roadmap.
At the event, Shengshu Technology simultaneously released its latest research achievement, Motus2 — a self-evolving general world model for robotic dexterous manipulation. Shengshu Technology defines the general world model as "a foundation model capable of uniformly understanding the present world, imagining possible futures, and changing the world through action," and proposes a five-level roadmap from L1 to L5: generating worlds, interacting with worlds, acting in worlds, autonomous world agents, and world organizers.
02/
Suunto Unveils 35-Gram Running Watch Suunto Run 2 and New Smart Heart Rate Belt
Recently, Qiming Venture Partners portfolio company Suunto officially launched the Suunto Run 2, designed for road running and marathon training, alongside the new Suunto Smart Heart Rate Belt 2.
The Suunto Run 2 weighs just 35 grams with a thickness of 11.7 mm, featuring a 1.32-inch AMOLED display with 466×466 resolution and peak brightness of 2000 nits — approximately triple that of its predecessor. It uses Corning Gorilla Glass and supports 50-meter water resistance. For sensors, it packs a 12-channel heart rate sensor paired with Suunto's next-generation proprietary algorithm to filter interference, and supports advanced running metrics including running power, vertical oscillation, and ground contact time. Positioning uses next-generation dual-frequency multi-band GNSS, simultaneously tracking L1 and L5 signals, with support for free global offline map downloads and local music storage. Battery life comes in three tiers: 24 hours in high-performance mode, 30 hours in endurance mode, and approximately 10 days in daily training scenarios. The China domestic version comes in midnight black, turquoise, and frost white, priced at RMB 2,499 for the 4GB version and RMB 2,799 for the 64GB version.
The simultaneously released Suunto Heart Rate Belt Gen 2 (SHRM 2) uses ECG heart rate detection** with a built-in six-axis IMU for running form analysis, approximately 460 hours of battery life, support for connecting to three devices simultaneously, and up to 20 hours of rolling memory.
Technology & Recognition
01/
Multiple Qiming Venture Partners Portfolio Companies Shine at Berlin IFA and Win Series of Awards
Recently, at the 2026 IFA Berlin, multiple Qiming Venture Partners portfolio companies brought their latest products to the global stage and achieved notable success at the IFA Innovation Awards 2026.
**Insta360 won one of the three highest honors (Master Awards) — "Best of Tech" — with its flagship gimbal camera Luna Ultra, which also received the "Best in Content Creation" award.
Xiaomi made its IFA debut with its largest-ever "Human × Car × Home" ecosystem showcase, using AI to connect smartphones, smart vehicles, and home devices. Multiple products won awards, including "Best in Smart Home" and "Best in Home & Entertainment."
viaim's AI agent earphones, viaim Rise, received the "Best in Audio" award and a "Best in Design" finalist nomination. Mifeng Technology won the All-Scenario Data Acquisition Technology Innovation Award on its first IFA appearance with its MEgo series data acquisition devices.
Roborock showcased its new cordless pool cleaning robot, with its F25 Pro Turbo Combo wash-dry integrated cleaning system earning a "Best in Smart Home" finalist nomination; Speediance's flagship home fitness system Gym Monster Ultra also received a nomination in the same category. UBTECH brought its newly released embodied intelligence humanoid robot to Berlin and announced an exclusive partnership with a European robotics systems integrator; Galaxy Universal demonstrated a fully autonomous G1 robot-operated unmanned store. Additionally, Makera exhibited its latest desktop CNC machine, and PETKIT showcased its AI pet care products.
02/
SinoUnited Health's International Medical Practice and CAR-T Cell Therapy Featured in The Wall Street Journal
Recently, The Wall Street Journal published a feature story on Shanghai's emergence as a new destination for cross-border medical care among cancer patients from developed countries including the United States, with particular focus on the international medical practice in CAR-T cell therapy at SinoUnited Hospital Shanghai, under Qiming Venture Partners portfolio company SinoUnited Health.
The report documented the real experience of a 25-year-old New Zealand patient: after being diagnosed with non-Hodgkin lymphoma, multiple rounds of chemotherapy, radiotherapy, and immunotherapy in his home country failed to control his condition; a hospital in Melbourne quoted CAR-T treatment costs of up to $600,000. In late June, he flew to Shanghai and received treatment under the guidance of hematologists at SinoUnited Health, paying less than half that amount, and learned on August 18 that his lymphoma had achieved complete remission. The report noted that China has currently approved nine CAR-T products, the highest number globally.
03/
CIX Technology's Agentic Compute Ecosystem Results Featured at Arm Everywhere China
Recently, the annual Arm Everywhere China conference was held in Shanghai. Qiming Venture Partners portfolio company CIX Technology (CiX) attended as an Arm ecosystem partner. CIX Technology witnessed the global debut of Arm's next-generation AI-native computing platform CSS for Mobile 2, participated in unveiling edge device technology achievements, and showcased multiple innovative terminal devices from ecosystem partners, two of which are powered by the CIX P1 chip; CIX Technology Chief Marketing Officer Danny Zhang was also invited to participate in two thematic roundtable forums, discussing computing innovation and industrial development opportunities in the agentic era with industry chain partners.
During the keynote presentation, Chris Bergey, Executive Vice President of Arm's Edge AI Division, introduced four innovative products for edge AI scenarios on stage, among which the CIX P1 workstation and Ugreen's HomeAgent 100 Pro both feature CIX Technology's self-developed P1 chip, becoming landmark implementations of high-performance products based on Armv9's latest architecture.
Terminal products based on the CIX P1 chip have been successively launched: in May, Lenovo introduced the AI Host Mini, positioned as an AI-native personal home edge device pre-installed with Tianxi Claw, supporting multi-terminal multi-agent collaboration, with AI computing power of 45 TOPS; Ugreen's HomeAgent 100 Pro, a home AIoT intelligent hub unveiled at IFA 2026, is also powered by the CIX P1 SoC, equipped with 32GB LPDDR5 memory, 128GB M.2 NVMe SSD, and 10GbE Ethernet port, with total AI computing power reaching 205 TOPS.
R&D Progress
01/
MediLink Therapeutics Announces Topline Data from Phase III Registration Trial of Tam-Peli in Relapsed Small Cell Lung Cancer
Recently, Qiming Venture Partners portfolio company MediLink Therapeutics announced interim analysis results from the TAISHAN-302 Phase III registration clinical trial of Tam-Peli (YL201), comparing it against topotecan in relapsed small cell lung cancer (SCLC) following progression after prior platinum-based chemotherapy with or without PD-L1 inhibitor treatment.
The trial met its primary endpoint of overall survival (OS), with Tam-Peli demonstrating statistically significant and clinically meaningful OS benefit, reducing patient death risk by 54% (median OS: 13.3 months vs. 9.4 months; stratified hazard ratio HR=0.46; P<0.0001). Key secondary endpoints also showed significant improvement: median progression-free survival of 7.4 months vs. 2.8 months, objective response rate of 59.1% vs. 9.7%. These results were presented as a late-breaking abstract by Professor Zhang Li of Sun Yat-sen University Cancer Center in an oral presentation at the Presidential Symposium of the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul.
Tam-Peli is an antibody-drug conjugate (ADC) targeting B7-H3, developed using MediLink Therapeutics' proprietary tumor microenvironment cleavable camptothecin-based toxin linker platform (TMALIN®). In January 2026, MediLink Therapeutics entered into an exclusive licensing collaboration with Roche for the Tam-Peli program.
02/
Insilico Medicine's Rentosertib Doses First Patient in Phase III Study GENESIS-IPF-3
Recently, Qiming Venture Partners portfolio company and generative AI-powered clinical-stage drug discovery technology firm Insilico Medicine (03696.HK) announced that its Phase III clinical trial for Rentosertib (ISM001-055/INS018_055) (CTR20262475, NCT07687459) has dosed its first patient at Peking Union Medical College Hospital in Beijing, China, with the same day seeing first patient enrollment at Shanghai Pulmonary Hospital.
This Phase III clinical trial is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to systematically evaluate the efficacy and safety of once-daily oral Rentosertib administered continuously for 52 weeks in treating idiopathic pulmonary fibrosis (IPF). The study is led by Principal Investigator Professor Xu Zuojun of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, with Academician Zhong Nanshan of the Chinese Academy of Engineering and Dean Chen Jing of Shanghai Pulmonary Hospital serving as co-principal investigators. The TNIK target addressed by Rentosertib was discovered by AI, with no previous association established with fibrosis.
Previous Issues
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol. 29, 2026.9.9
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming Venture Partners has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions, with over 80 companies recognized as unicorns or super-unicorns in their respective industries.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), APT Medical (688617.SH), Sanyou Medical (688085.SH), AmoyDx (300685.SZ), Sinocelltech (688520.SH), Insilico Medicine (03696.HK), AusperBio, Yuanxin Technology, MediLink Therapeutics, Leads Biolabs, StepFun, and others.